A Rapid Approach to Streamlined CART Therapies and Reduced Cost of Goods

In this eBook, Kincell Bio and Syenex present data demonstrating how RapidCell™ technology can simplify CAR-T manufacturing by eliminating multiple process steps, reducing manufacturing operations by approximately 40%, and lowering estimated cost of goods by up to 55%. The study highlights a streamlined workflow that delivers robust cell growth, high T-cell purity, strong CAR expression, and potent therapeutic performance.

Download the eBook to explore how next-generation manufacturing technologies can help accelerate CAR-T production while reducing costs and improving scalability.